The FOLFOX4 (NOTE: FOLFOX and not just 5FU) regimen increased the probability that a patient would be alive and disease-free at 3 years by 5.3% (except >70 years). However, survival probability dropped drastically stage IIIB onwards with Mayo clinic protocol.
With Mayo clinic regimen, five year overall survival probability in the age groups >70 years group had three years survival probability of 50% but no patient survived till five years of starting the treatment (p<0.0001). With FOLFOX4 protocol, the five year survival probability was 0% for >70 years; for rest of the age groups, survival ranged between to 80-88%.
The five year survival probability with Mayo clinic and FOLFOX4 protocol in stage IIIA was 80%; for stage IIIB, it was 55% while for stage IIIC, it was 50%. Both protocols yielded 95% survival in stage II. However, three year survival with FOLFOX4 protocol was 50%. (p < 0.0001).
http://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/combinationregimen/oxaliplatin5fu.aspx
The FOLFOX4 regimen increased the probability that a patient would be alive and disease-free at 3 years by 5.3%.
Cleveland ClinicStage IV Colorectal Cancer
When diagnosed as advanced metastatic disease, colorectal cancer (CRC) is traditionally associated with a poor prognosis, with 5-year survival rates in the range of 5% to 8%. The actual survival rate has remained unchanged over the past 35 to 40 years. However, during the past 5 years, significant advances have been made in chemotherapy treatment options, such that improvements in 2-year survival rates are now being reported — median survival rates of 21 to 24 months in patients with metastatic disease.
dianetavegia wrote:FOLFOX is generally given to patients who are Stage I to Stage III and not Stage IV. More aggressive and harsher chemo is generally used for Stage IV. This link list the usual side effects of FOLFOX.http://www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/chemotherapy/combinationregimen/oxaliplatin5fu.aspx
Yes, many studies. Terminology can be tricky. 50% of all Stage III have recurrence. So 50% of Stage III could potentially be cured by surgery alone. Doctors include this 50% in their 'survival stats'.The FOLFOX4 regimen increased the probability that a patient would be alive and disease-free at 3 years by 5.3%.
I would find out if she's had a PET scan and if not, ask for one. Spots on her liver and lung at age 90, if cancerous, would strongly suggest she's more sick than you think. Chemo only cures 3 kinds of cancer. Two are children's cancers and one is a hodgkin's lymphoma. The rest, it can shrink, make 'disappear' but eventually regrow.
Chemo is poison and has so many side effects. One of our members went into cardiac arrest and is a young person!Cleveland ClinicStage IV Colorectal Cancer
When diagnosed as advanced metastatic disease, colorectal cancer (CRC) is traditionally associated with a poor prognosis, with 5-year survival rates in the range of 5% to 8%. The actual survival rate has remained unchanged over the past 35 to 40 years. However, during the past 5 years, significant advances have been made in chemotherapy treatment options, such that improvements in 2-year survival rates are now being reported — median survival rates of 21 to 24 months in patients with metastatic disease.
I would only consider mom to be 'advanced' if she has spread to her liver/ lungs and not the one lymph node. Still, if only 3 to 5 people out of 100 live longer due to chemo, I'd take the chance and not give chemo to a 90 year old woman.
Push for a PET scan. That would clear up the issue of spots on the liver and lung. I wouldn't make any decision until I knew just where the cancer IS and IS NOT. A lymph node can many times be surgically removed if there is no other cancer.
Again, I'm a bit anti chemo because of all my side effects 7 1/2 years past my last treatment AND I wasn't given chemo after my liver resection because it wasn't deemed necessary or known to be helpful. My onc said if I to
Not All Stage II Tumors Are Alike
Though stage II tumors are grouped together, there are subgroups that appear more likely to relapse and may, in turn, derive more benefit from adjuvant chemotherapy. The 5-year survival for people with T3N0 tumors is 85% versus 72% for those with T4N0 tumors, yet these are both classified as stage II. A tumor may have other high-risk features that may predict a higher chance of recurrence. While the presence of these high risk features can prompt a discussion between the physician and patient about the use of chemotherapy, most clinical studies have found only small improvements, if any, in survival (2%-5%) with the addition of chemotherapy in stage II disease. Therefore, each person must make his/her own educated decisions regarding treatment based on the information available.
It is also important to note that stage II tumors have previously always been considered as just another phase of the same cancer and that stage II cancers just have disease extent that is between stages I and III. More recently, experts think it is possible that stage II tumors are genetically different than stage III tumors, which may explain the very different responses of these tumors to the same treatments. While we have no definitive answers to this question, it is something to consider when looking at the various features of stage II and III tumors that predict recurrence and treatment benefit.
High Risk Features
As already noted, the depth of invasion (T3 vs. T4) is one high-risk feature. People found to have a bowel perforation or obstruction, at the time of diagnosis, are also at higher risk for recurrence. The "grade" of the tumor can also affect recurrence risk. When the tumor is examined by the pathologist, it is assigned a "grade", which tells how abnormal the cells appear. The more a tumor cell looks like a normal cell, the more well-differentiated it is. Grading is broken down into three groups:
Grade 1: also called well differentiated. Cells appear the most similar to normal colon cells
Grade 2: also called moderately differentiated.
Grade 3: also called poorly differentiated. Cells appear the most abnormal and tend to grow more aggressively.
Grade 3, or poorly differentiated cells, are considered high risk. The pathologist may also identify invasion of the blood vessels, lymph nodes or nerves by cancer cells (lymphovascular or perineural invasion), which is considered high risk.
Prior to surgical removal, a blood test to detect CEA (carcinoembryonic antigen) is done. CEA is a substance produced by the cancer cells, called a tumor marker. Elevated levels (CEA>5 ng/ml) prior to surgery are thought to infer a higher risk of recurrence.
Lastly, the number of lymph nodes examined can put a tumor in the high-risk category. If fewer than 12 lymph nodes are removed and examined, the risk of recurrence is higher and the overall survival lower. In studies, the 5-year overall survival (OS) correlates to the number of lymph nodes removed (1-7 LNs = 49.8% OS, 8-12 LNs = 56.2%, >12 LNs = 63.4%). It is not clear if this is because examining more lymph nodes in these patients would have found their tumors to be stage III, or because the surgical removal was less than complete, or perhaps both. We don't know for sure, but this finding often drives the decision to use adjuvant chemotherapy in patients with fewer than 12 LNs removed.
Studies have found that the presence of two or more high-risk factors is most likely to increase the risk of recurrence. In one study, patients whose stage II tumors did not have any high-risk features have been reported to have a 5-year survival rate of 95%. So as you can see, there are many things to consider when deciding whether or not to treat with adjuvant therapy.
Unfortunately, all of these "high-risk" features suggest an increased risk of recurrence and/or decreased survival. However, studies have not been able to show that the addition of chemotherapy provides any benefit, and professional guidelines are not in agreement. Two groups do not support the use of adjuvant chemotherapy for stage II disease, even in the presence of high-risk features, due to the very small benefit derived (2-5%) from this potentially toxic therapy. Meanwhile, a third professional group suggests that adjuvant chemotherapy should be considered for patients with high-risk features. Patients and physicians are often not comfortable choosing to forgo adjuvant therapy. Reviews have found that more than ¼ of patients with stage II disease receive adjuvant therapy, despite a lack of evidence that it improves survival.
fordodo wrote:...She had surgery, recovered and has been on 5FU alone since September. This past scan a lymph node grew from 4.7 to 5.5;;;
fordodo wrote:Folfox's neuropathy issues make me question if its worth it for her to try? A different doctor we know mentioned the mini dose of 65 to access tolerance and this seems somewhat more reasonable. I have also wondered if pushing for Folfiri is a better option. I am an avid researcher and believe that sometimes the best advice you can receive is from those who have been through it...so I am turning to all of you in hopes you can offer opinions and advice. My Mother In law is an amazing woman and the last thing I want is for her to suffer. Thank you in advance!
Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”
Users browsing this forum: Google [Bot] and 387 guests